BLENREP 100 MG
BELANTAMAB MAFODOTIN : 100 MG · DIN 02559625 · GLAXOSMITHKLINE INC
Health Canada status: MARKETED
What is BLENREP?
BLENREP 100 MG contains BELANTAMAB MAFODOTIN : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02559625, held by GLAXOSMITHKLINE INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 11-Aug-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BLENREP used for?
In combination with bortezomib/dexamethasone or pomalidomide/dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02559625 |
|---|---|
| Brand name | BLENREP |
| Generic / active ingredient | BELANTAMAB MAFODOTIN : 100 MG |
| Manufacturer | GLAXOSMITHKLINE INC |
| Strength | 100 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription Recommended |
| ATC code | L01FX15 BELANTAMAB MAFODOTIN |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 11-Aug-2025 |
How is it administered?
Administered by IV infusion over 30 minutes. BVd regimen: 2.5 mg/kg every 3 weeks. BPd regimen: 2.5 mg/kg (Cycle 1), then 1.9 mg/kg every 4 weeks (Cycle 2+).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Reconstituted: Refrigerated (2°C-8°C) or room temp (20°C-25°C) for 4h. Diluted: Refrigerated (2°C-8°C) for 24h; room temp for 6h (including infusion). Do not freeze.
How is it supplied?
Single-use vials (70 mg with blue cap or 100 mg with orange cap) containing sterile lyophilized powder.
Contraindications
Hypersensitivity to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Serious Warning: Can cause corneal epithelium changes resulting in ocular symptoms, severe visual impairment, and/or corneal ulcers. Requires regular ophthalmic exams.
What can be used instead?
Other Canadian products sharing ATC code L01FX15 BELANTAMAB MAFODOTIN. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BLENREP | 70 MG | POWDER FOR SOLUTION | GLAXOSMITHKLINE INC | MARKETED | DIN 02559617 |
Who else supplies BELANTAMAB MAFODOTIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BELANTAMAB MAFODOTIN appears in 4 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.